Ossur Hf

Aktie
WKN:  ISIN:  USX6026B1062
Keine aktuellen Kursdaten verfügbar
Depot/Watchlist
Dieses Wertpapier ist nicht mehr handelbar.
Marktkapitalisierung *
-
Streubesitz
-
KGV
-
Index-Zuordnung
-
Ossur Hf Chart

Werbung

Mehr Nachrichten kostenlos abonnieren

E-Mail-Adresse
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Ossur Hf Termine

Keine Termine bekannt.

Prognose & Kursziel

Keine aktuellen Prognosen oder Kursziele bekannt.

Ossur Hf Prognose 2026: Einstufung & Empfehlung von Analysten

Ossur Hf Kursziel 2026

  • Die Ossur Hf Kurs Performance für 2026 liegt bei -.

Einstufung & Prognose 2026

  • Analysten haben Ossur Hf eingestuft: Analysten empfehlen Ossur Hf zum Kauf, zum Halten und zum Verkauf.
  • Analystenschätzungen: Laut Einschätzung der Analysten birgt die Ossur Hf Aktie ein durchschnittliches Kurspotential 2026 von .

Stammdaten

Aktienanzahl 425,38 Mio.
Aktientyp Stammaktie

Community-Beiträge zu Ossur Hf

  • Community-Beiträge
  • Aktuellste Threads
Avatar des Verfassers
Tamakoschy
Q1 19
https://www.ossur.com/corporate/investor-relations https://assets.ossur.com/library/40759 https://assets.ossur.com/library/40760 Highlights  Sales growth of 19% in local currency in the quarter and organic sales growth of 8%.  The prosthetics segment grew 10% organic and the B&S segment grew 5% organic. Growth in both business segments can be attributed to strong sales of high-end innovative products.  Gross profit margin was 64% compared to 62% in the comparable quarter. The increase is driven by positive impact from changes in product mix, savings from the ongoing efficiency initiatives, and scalability in manufacturing.  EBITDA margin was 19% compared to 14% in the comparable quarter. EBITDA margin excluding the impact of IFRS 16, was 16% in Q1 2019. Higher EBITDA margin is driven by positive changes in product mix, savings from the ongoing efficiency initiatives, scalability, and currency movements. It should be noted that EBITDA margin is seasonally weak in the first quarter of the year.  Net profit grew by 37% and amounted to 9% of sales. Growth in diluted EPS amounted to 38%.  Cash generated by operations amounted to 10% compared to 4% of sales in the comparable quarter.  Össur acquired 985,364 of own shares through the ongoing share buyback program for USD 5 million in Q1 2019.  Dividends of DKK 0.14 per share, corresponding to approximately USD 9 million or 11% of net profit in 2018, were paid out in March 2019.  5,430,259 own shares with a nominal value of ISK 1 each were cancelled at the end of March 2019. The share capital of Össur is now ISK 425,377,804.  The financial guidance for the full year 2019 is unchanged, 4-5% organic sales growth, ~23% EBITDA margin before special items*, 4-5% CAPEX of sales, and an effective tax rate of 23-24%. Jon Sigurdsson, President & CEO, comments: “The sales growth in the first quarter was strong with good growth from both business segments and all market regions with the prosthetics segment and the APAC region at the forefront. We are pleased to see that our highend innovative products were driving growth, including the new PROPRIO FOOT® which was fully launched in all markets in the quarter and has received a good response. We increased our profitability in the quarter compared to last year with favorable changes in product mix, additional savings from the ongoing efficiency initiatives, and scalability. Cash generation was furthermore strong in the quarter bearing in mind that the first quarter of the year is seasonally the weakest in terms of profitability and cash generation.”
Jetzt anmelden und diskutieren Registrieren Login
Zum Thread wechseln

Häufig gestellte Fragen zur Ossur Hf Aktie und zum Ossur Hf Kurs

Nein, Ossur Hf zahlt keine Dividenden.